Argenx, Calliditas Hit The Ground Running After FDA Approvals
Green Lights For Vyvant and Tarpeyo
Two European companies - the Belgian-Dutch biotech Argenx and Calliditas of Sweden - are going it alone to commercialize their just-approved rare disease therapies in the US.
You may also be interested in...
Despite a US approval for its novel FcRn inhibitor Vyvgart in gMG, the firm has realistic expectations of sales, factoring in concerns about COVID-19 and lagging medical education.
Merck will develop Chord’s lead drug candidate, an oral version of cladribine, for the treatment of neuromyelitis optica spectrum disorders and generalized myasthenia gravis.
The Swiss group has delivered on its promise to secure more deals in the nephrology space by bagging the rights in Europe, Australia and New Zealand to sparsentan, which is deep into a Phase III program for focal segmental glomerulosclerosis and IgA nephropathy.